Anticoagulation to prevent stroke in atrial fibrillation

BMJ

Volumn 321, Issue 7269, 2000, Pages 1156-

  Fitzmaurice, D A ^a   Mant, J ^a   Murray, E T ^a   Hobbs, F D R ^a   Oswald, Nigel ^b   Oliver, M D ^a   Ono, Ayumu ^c   Bellelli, Giuseppe ^d   Bianchetti, Angelo ^d   Trabucchi, Marco ^e  

^a Primary Care Resource and Development Centre ^*  (United Kingdom)

^b TEESSIDE UNIVERSITY   (United Kingdom)

^c Otsuki Hospital   (Japan)

^d Ancelle della Carita Hospital   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; GENERAL PRACTICE; HEART ATRIUM FIBRILLATION; HOSPITAL CARE; HUMAN; LETTER; PATIENT SELECTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; STROKE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; NOTE; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; FAMILY PRACTICE; HUMANS;

EID: 0034605610     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.321.7269.1156     Document Type: Letter

References (21)

1. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000; 320: 1236–1239. (6 May.)
2. Copland M, Tait RC, Walker ID. A retrospective follow-up study of oral anticoagulant control and haemorrhagic complications in an elderly population with atrial fibrillation. Br J Haematol 2000; 8(S1): 56.
3. Connolly SJ. Anticoagulation for patients with atrial fibrillation and risk factors for stroke. BMJ 2000; 320: 1219–1220. (6 May.)
4. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000; 320: 1236–1239. (6 May.)
5. Oswald N, Bateman H. Applying research evidence to individuals in primary care: a study using non-rheumatic atrial fibrillation. Fam Pract 1999; 16: 414–419.
6. Lip GYH, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the west Birmingham atrial fibrillation project. Br J Gen Pract 1997; 47: 285–289.
7. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999; 318: 1324–1327.
8. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 352: 1167–1171.
9. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000; 320: 1236–1239. (6 May.)
10. Connolly SJ. Anticoagulation for patients with atrial fibrillation and risk factors for stroke. BMJ 2000; 320: 1219–1220. (6 May.)
11. Moss F. Junior doctors' pay: a wake-up call to the NHS. BMJ 2000; 320: 1224. (6 May.)
12. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000; 320: 1236–1239. (6 May.)
13. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–1457.
14. Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28: 2382–2389.
15. Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage B. Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J 1999; 137: 307–312.
16. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469–473.
17. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000; 320: 1236–1239. (6 May.)
18. Ansell JE. The quality of anticoagulation management. Arch Intern Med 2000; 160: 895–896.
19. Bellelli G, Barbisoni P, Gusmeri A, Sabatini T, Rozzini R, Trabucchi M. Underuse of anticoagulation in older patients with chronic atrial fibrillation: malpractice or accuracy? J Am Geriatr Soc 1999; 47: 1034–1035.
20. Rozzini R, Sabatini T, Trabucchi M. Risk assessment and anticoagulation in atrial fibrillation in the elderly: malpractice or accuracy? Stroke 1999; 30: 2239–2240.
21. Rozzini R, Sabatini T, Bellelli G, Trabucchi M. Anticoagulation in elderly patients with chronic atrial fibrillation: the need for geriatric assessment. Age Ageing (in press).